Executive summary

42 patients with locally advanced head and neck tumors treated with PBT were retrospectively analyzed in this study. Compared to VMAT plans, PBT plans showed a significant reduction of the mean dose and max dose to OARs, with the largest reduction mean dose in the contralateral cochlea and parotid glands at 71% and 75%. With a median follow up of 27 months, this study reported the OS rate of 44.75% at 4 years and PFS of 73.28% at 2 years. The majority of patients developed CTCAE grade I dermatitis, mucositis, or both.

Top cancer treatments